$735.16 Million in Sales Expected for Illumina, Inc. (ILMN) This Quarter
Equities analysts expect that Illumina, Inc. (NASDAQ:ILMN) will report sales of $735.16 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Illumina’s earnings, with the lowest sales estimate coming in at $728.41 million and the highest estimate coming in at $741.30 million. Illumina reported sales of $619.35 million during the same quarter last year, which would suggest a positive year over year growth rate of 18.7%. The firm is scheduled to announce its next earnings results on Tuesday, January 30th.
On average, analysts expect that Illumina will report full-year sales of $735.16 million for the current fiscal year, with estimates ranging from $2.70 billion to $2.72 billion. For the next fiscal year, analysts anticipate that the business will post sales of $3.07 billion per share, with estimates ranging from $2.97 billion to $3.19 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Illumina.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business’s revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.97 earnings per share.
ILMN has been the subject of several recent research reports. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target for the company in a research report on Thursday, July 27th. Deutsche Bank AG set a $175.00 target price on Illumina and gave the company a “hold” rating in a research report on Friday, July 28th. BidaskClub upgraded Illumina from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 1st. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research report on Wednesday, August 2nd. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $250.00 target price on shares of Illumina in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $200.88.
Illumina (NASDAQ ILMN) opened at $215.35 on Friday. The company has a market capitalization of $30,959.30, a PE ratio of 62.00, a P/E/G ratio of 3.50 and a beta of 0.74. Illumina has a 12-month low of $119.37 and a 12-month high of $215.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73.
In other Illumina news, SVP Oene Mark Van sold 9,729 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57. Following the sale, the senior vice president now directly owns 24,908 shares of the company’s stock, valued at $5,263,807.64. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 2,540 shares of the company’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $197.39, for a total transaction of $501,370.60. Following the completion of the sale, the director now directly owns 539,176 shares in the company, valued at $106,427,950.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 172,446 shares of company stock worth $35,486,114. Insiders own 0.89% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after purchasing an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Illumina by 3.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after purchasing an additional 76,452 shares during the last quarter. Capital World Investors raised its position in shares of Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new position in shares of Illumina during the 2nd quarter worth about $211,584,000. 90.76% of the stock is currently owned by institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.